Breaking News

Northern Dynasty Minerals Ltd NAK Stock News

Northern Dynasty Minerals Ltd (NYSEMKT: NAK) is having yet another incredible day in the market today as investors continue to track the Pebble Project. However, as I dug around today, I found an interesting concept. Many on message boards are speculating that Rio Tinto is building funds for a buyout. Today, we’ll talk about what we’ve seen from Rio Tinto, why some believe that they are preparing for an NAK takeover, and what we’ll be watching for ahead.





What We’re Seeing From Rio Tinto

As mentioned above, many investors at NAK have been under the impression that the company is gearing up for a takeover and most believe that Rio Tinto is going to be the one to make the offer. The reason for this is relatively simple. Recent news surrounding RIO suggests that they are gearing up for something big financially.




Recently, the investment firm Macquarie said that RIO would be selling some of its assets, hoping to raise up to $10 billion. The firm said that the London-based company could bring in between $3.3 and $4.3 billion should it sell its outstanding coal operations. On top of that, Rio Tinto could raise up to $2.8 billion should it choose to sell its aluminum and smelting operations. The investment firm believes that in total, between all assets it is considering selling, it could bring in roughly $9.9 billion.

Is This To Acquire NAK?

As mentioned above, I’ve seen several messages on message boards suggesting that at the moment, Rio Tinto is building up funds in order to acquire Northern Dynasty Minerals. First and foremost, I want to make it clear that this is nothing more than speculation at the moment. RIO may just be building funds to move forward with their own operations. However, it’s hard to argue that the company would gain quite a bit from acquiring NAK.

If I was asked about a potential acquisition of NAK a year ago, I would have said it is too early in the game. However, today, things are very different. Throughout the year, things have changed in a big way with regard to the Pebble Project, and if things keep going in this direction, the project could be an overwhelmingly profitable one! The company has gotten to the point where they will be able to work toward permits for the project, which was a long fight and well won.

As a result, they are getting overwhelmingly close to beginning construction of what could be one of the largest mines in the world. So, it wouldn’t be inconceivable if a big company like RIO wants to take a piece of the pie. So, as to the question above, no one quite knows if Rio Tinto is raising funds to acquire Northern Dynasty Minerals, but it is definitely not out of the question.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on RIO and NAK. In particular, we’re interested in following the asset sales at RIO and seeing if the company is indeed interested in acquiring NAK. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 381
Opexa Therapeutics OPXA Stock News

Opexa Therapeutics Inc (NASDAQ: OPXA) is having a relatively strong day in the market today. At least, it has been in the green all morning. The reason is relatively simple. Today is the day that investors will vote with regard to a proposed merger. At the moment (10:36), OPXA is trading at $1.10 per share after a gain of $0.01 per share or 0.93% thus far today.





OPXA Investors Await Big News

As mentioned above, today could be a big day for Opexa Therapeutics. The company recently announced that it has intentions of acquiring Acer Therapeutics, Inc. However, before doing so, they need to gain support from investors. That’s where today comes in. Today is the last day for shareholders to vote with regard to the potential merger.




At the moment, Institutional Shareholder Services Inc. and Glass, Lewis & Co. are both recommending that shareholders vote for the proposed merger. If the merger goes through. Acer Therapeutics will become the wholly owned subsidiary of Opexa Therapeutics, which would be the surviving company in the merger.

However, it’s important that investors take the time to consider the options here and make their vote heard, especially if they are for the merger. After all, if you are for the merger and fail to vote, your vote will be the same as an “Against” vote. If you are a shareholder and would like to cast your vote, you can do so by calling:

Advantage Proxy, Inc.

Toll Free: (877) 870-8565

Collect: (206) 870-8565

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on OPXA. In particular, we’re interested in following the news surrounding the potential merger and hoping that the merger does indeed get executed. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Chicago Bridge & Iron Company N.V. CBI Stock News

Chicago Bridge & Iron Company N.V. (NYSE: CBI) is having an interesting day in the market today. While the stock found itself in the red early on, most recently, the stock has been spiking as the result of rumors. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:59), CBI is trading at $15.99 per share after a gain of $0.82 per share or 5.41% thus far today.





CBI Gains On Takeover Chatter

As mentioned above, Chicago Bridge & Iron Company is having an interesting day in the market early on today. While the the stock was in the red early on, most recently, the stock has been spiking upward as rumors start to break. The rumor is that the company will soon be taken over at a price of $25.50 per share. This represents an overwhelmingly strong premium. However, as most market rumors, this one is relatively vague. There is no insinuation of who may be interested in purchasing the company and finding the source of the rumor is proving to be nearly impossible.




As is the case every time we cover rumors, it’s important that we remind readers that the CBI rumor isn’t the only one we’ve seen recently. In fact, rumors seem to be a daily occurrence in the market. Like most rumors, market rumors generally lack validity. In this case, because the rumor is overwhelmingly vague and tracking the source is nearly impossible, we aren’t getting our hopes up and don’t believe that you should either. So, if you’re going to trade on this news, please be sure to do so with caution.

Stop wasting your time! Start finding winning trades in minutes with Trade ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CBI. In particular, we’re interested in learning if there is any validity to these rumors. While we don’t believe that the company will be taken over, anything can happen in the market. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 866
Delcath Systems, Inc. DV32 DCTH Stock News

Delcath Systems, Inc. (FRA: DV32) (Previously NASDAQ: DCTH) is having yet another rough start to the trading session this morning. As the company continues to burn bridges with its investors, it seems to be on a bit of a free fall as of late. As is normally the case, our partners at Trade Ideas were the first to alert us to today’s declines. Currently, DV32 (previously DCTH) is trading at $0.06 per share after a loss of 0.002 per share or 3.23% thus far.





The Problem With DV32 (DCTH) Is A Big Disconnect Between Management And Investors

As mentioned above, Delcath Systems has been finding its way downward in the market as of late, and for good reason. There has been a big disconnect between investor goals and the goals of management recently. Most recently, the disconnect has had to do with plans to process a reverse split.

You see, DV32 (DCTH) wanted to process a 500 to 1 reverse split, bringing the value of their stock well above the required $1 per share and opening the door to funds as well as eliminating some near term debt obligations. However, in order for this to happen, the company needed approval from investors, and that vote didn’t go well.




However, that wasn’t for lack of the company trying to push investors in the direction that they wanted them to go. Not only was there an extension to the deadline on the vote when it was clear that investors planned on voting no, DV32 (DCTH) all-but harassed investors to try to get them to change their votes.

Through the use of a call center, Delcath Systems continuously called investors in an attempt to get them to change their votes. I’ve received several messages from investors informing me that not only were they calling, they were calling several times per day and largely harassing investors into voting yes. I’ve also received a couple recorded phone calls in which the call center clearly misled investors with regard to voting deadlines and showing that c-level management was unaware of just what the representatives of these call centers were doing, or at least they claim to be unaware. Nonetheless, the harassment continued.

The Reverse Split Failed Anyway

Regardless of how much DV32 (DCTH) tried to get investors to vote yes on the reverse split, they ultimately failed. As a result, the company recently reached out to investors with a press release, letting them know that the company would be delisted from the NASDAQ and would commence trading on the OTC market. However, there were a few things that investors wanted to see that Delcath Systems management didn’t offer.

Throughout the time I’ve been following the company, I’ve seen several messages and even a petition where investors were hoping that the management at the company would reduce their exorbitant salaries. However, at the moment, these salaries remain the same. Also, none of the management at DV32 (DCTH) have any skin in the game. Investors would like for them to invest, or take some of their pay in shares. However, that hasn’t happened either.

The Problem Isn’t In The Product

If there is one thing that DV32 (DCTH) does have going for them is their product. The company has received approval in Europe for Chemosat and treatments in the region are going well. The company is also looking for approval in the United States. However, considering the current financial standpoint of the company, it may be difficult for the company to stay afloat through the next regulatory catalyst.

What’s Next

The truth is that I have no connection to the c-suite at Delcath Systems, nor any sources inside the company. So, I know just about as much about their future plans as you do. However, considering that the RS was voted down and the financial position of the company, I wouldn’t be surprised to see the company put itself up for sale. After all, their intellectual property is valuable, regardless of how poorly management is performing. If a strong management team took over the product, we could see great things happen. However, because of various measures that the company has in place to protect management, the only way this is likely to happen is if the company were to sell its assets or decide to sell itself!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on DV32 (DCTH). In particular, we’re interested in seeing what moves the company makes in the months ahead to stay afloat. We’re also watching to see if management makes the changes that the investors would like to see or considers selling the company. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Rite Aid Corporation RAD Stock News

Rite Aid Corporation (NYSE: RAD) is having a relatively strong start to the trading session in the pre-market this morning, and for good reason. The company announced today that it has received regulatory clearance to sell 1,932 stores and more. Of course, this led to excitement among investors, pushing the stock upward and prompting our partners at Trade Ideas to alert us to the movement. At the moment (8:30), RAD is trading at $2.76 per share after a gain of $0.03 per share or 1.10% thus far today.





RAD Gains On Regulatory Clearance To Sell Stores

As mentioned above, Rite Aid Corporation is having a relatively strong start in the pre-market hours this morning after it announced that it has received regulatory clearance to sell nearly 2,000 stores. Under the deal, Walgreens Boots Alliance, Inc. (NASDAQ: WBA) will purchase 1,932 stores, 3 distribution centers and related inventories. Under the terms of the agreement, WBA will be paying RAD a total of $4.375 billion in cash for the acquisition of the stores on a cash-free, debt-free basis. The deal also gives Rite Aid the ability to purchase generic drugs that are sourced through an affiliate of WBA at a cost that is equivalent to Walgreens for a period of 10 years.

The agreement is part of a deal that was announced earlier. However, the deal has been amended, giving RAD the ability to retain approximately 250 additional stores when compared to the original agreement that was signed in 2017. In a statement, John Standley, Chairman and CEO at RAD, had the following to offer…




Securing regulatory clearance provides us with a clear path forward to realize the benefits of this transaction. With a compelling and more profitable store footprint in key markets, enhanced purchasing capabilities and a stronger balance sheet and improved financial flexibility, we are well positioned to implement our plans to deliver improved results… I am proud of our entire Rite Aid team for their extraordinary efforts during this process and their tremendous dedication to taking great care of our customers and patients. We are committed to supporting a smooth transition as we remain focused on delivering a great customer experience, improving our business and creating value for all of our stakeholders.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on RAD. In particular, we’re interested in following the story surrounding the sale of the stores and excited to see how the company uses the funds and the new opportunities on the generic purchasing front. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 216
Aytu BioScience AYTUD Stock News

The battle is underway for market share in the $2 billion testosterone replacement therapy (TRT) market, and two of the companies that are working hard to secure their stake is Antares Pharma and Aytu BioScience. Although both companies have their own recipe for testosterone replacement success, which of them has the product that can pump up near-term investor rewards?





Playing the role of “wise choice” investor is an arduous task, and when faced with determining which company, Antares Pharma or Aytu BioScience, will likely attract market share from its innovative TRT product, even experienced investors may get blinded by some similarities between the two products. However, upon closer inspection, the distinctions between the two are vast, and only one product of the two is likely to emerge as the potential market disruptor in this multi-billion dollar market.

Let’s see what each has to offer.

Can Antares Pharma Get Xyosted™ Approved?

First, let’s look at Antares Pharma’s potential contribution to the TRT market. For its part, ATRS is planning to offer Xyosted™, a single use, fixed dose subcutaneous testosterone enanthate that gets delivered via auto-injection. The auto-injection is intended to allow for rapid subcutaneous delivery of a viscous testosterone solution through a single use, 27-gauge needle. For those paying close attention, the modifier “potential” was used to describe the treatment because Xyosted™ is not yet FDA approved for market, but according to Antares has a PDUFA review date set for October 20, 2017. If all goes well during the application process and FDA approval is earned, ATRS says that it expects to launch the product in December of 2017.




Antares is not alone in its attraction to this lucrative market, and several companies are currently working to take a bite out of the multi-billion dollar TRT pie. But, as many investors understand, the small window of opportunity may only exist for a company that can truly deliver a better product for TRT patients, replacing treatments that are littering the TRT landscape with Black Box warning safety labels.

Efficacy and safety will be the key measures of success, and Antares has touted that roughly 92.7% of Xyosted™ test subjects reached the trials primary endpoint after 12 weeks of treatment. That’s a good thing. Additionally, almost all of the patients reported the injection itself was relatively painless, which is also a welcome sign for Antares. However, and not to rain on the ATRS parade, while most patients did not report an extreme level of physical discomfort, the larger question remains as to whether clinicians consider the current generic injectables as overly painful, an important issue since over 4 million prescriptions were written last year for generic testosterone injectables. That’s a big problem facing ATRS and Xyosted™, and the company is hoping to influence doctors to prescribe a product that may hurt less, but not offer much more therapeutic benefit at a much higher cost to patients. Therein lay the struggle. And, even if Xyosted™ gets approved, ATRS may be fighting an uphill battle to gain favor with prescribers that work to keep the cost of medication down for their patients. The dilemma that clinicians may face if prescribing Xyosted™ is that it does not cost just pennies more, it will cost a patient hundreds more in monthly cost. And, despite the fact that the pharmaceutical industry is flush with cash and fills an office with catered meals and friendly sales reps, at the end of the day, cost matters.

Perhaps if Xyosted™ was the first and only injectable on the market, the relative ease of use might be alluring to patients. But, the truth of the matter is that the market is saturated with FDA approved generic injectables, and the cost difference between an approved Xyosted™ and a generic product is substantial. The patient cost estimates for Xyosted™ run high, with treatment prices expected to cost upwards of $400 per month, with some estimates hitting a higher monthly price tag of roughly $500 per month. Now, although men may be willing to pay any price to get the TRT they require, the current cost of generic injectable treatment is less than $100 per month, and reports of uncomfortable or painful injection sites are not causing a movement for change amongst users. Thus, if the current generic treatment is not all that painful and may deliver similar results for up to $5,000 a year less than Xyosted™, ATRS may have its hands full when trying to convince prescribers to offer their treatment.

But, the battle may not end there. Because of the cost, questions abound as to whether managed care and Medicare payors will give enough credence to Xyosted™ simply because of its relatively pain-free delivery method. And, not only that, ATRS may face additional pressure if an approved Xyosted™, even with its premium price, is not able to demonstrate superiority in efficacy or safety over currently available generic injectables. Another thing, if history serves as a guide, the likelihood for broad support of a high-priced medication that does not provide substantial benefit to the patient often finds its level of interest from insurers to be considerably and materially less responsive for reimbursable coverage.

Antares, by the way, is not oblivious to the potential challenge. They have acknowledged that only about 50% of the managed care accounts that they will be targeting upon approval will consider NOT blocking access to Xyosted™ during the first six months on the market. That may be a half glass-full scenario for ATRS, but, as that glass empties, they then face the potential that approximately 50% of the insurance companies will not even consider coverage. Simply put, if an approved Xyosted™ does not provide a substantial improvement in intended results, many patients may be hard pressed, and reluctant, to fork over $400-$500 per month, and likely opt for a treatment alternative which may cost less than a hundred bucks per month.

In a nutshell, ATRS is likely to receive FDA approval for Xyosted™, but from an investor’s point of view, a determination must be made as to whether an approved Xyosted™ brings with it enough clinical evidence and real patient benefit to substantiate its high price. And, if investors can justify their reasoning in all things Xyosted™, then they must also hold onto the hope that the current 50% interest by insurers does not trend back toward zero.

Aytu BioScience Brings Natesto®

This is no exaggeration, Aytu BioScience may be the sleeping giant in the sector. They offer Natesto®, the only nasally administered, two to three doses per day TRT treatment on the market. Quietly compounding sales, the prescription rates for Natesto® have risen more than 300% in just the past four months and has gained sequential prescription writing momentum throughout all of 2017. Now, investors should not expect this potential giant to emerge as a leader overnight, but, if Natesto® continues to prove itself as the only NON-Black Box warning topical TRT product that can provide meaningful therapeutic benefit without the severe potential side effects, investors may indeed get treated to significant Natesto growth spurts in the months to come.

Contrary to Antares’ hope for 50% reimbursement levels, at Aytu, provider support is growing, and Natesto® is already receiving coverage from many managed care providers. Following the momentum, AYTU management has stated that they are actively pursuing additional coverage agreements during the next several months. Beyond just insurers, though, and proving a clear value proposition from a potentially approved Xyosted™, is that Natesto® ranges between $25 – $100 per month for treatment, and in no case will a patient ever pay more than $150 when using Aytu’s AssureRx patient co-pay program. Just considering price, the difference in cost between Xyosted™ and Natesto® may save a patient upwards of $475 per month in out-of-pocket expense unless Antares offers a similar program.

Natesto® loses no points in the convenience department, either. The product is easy to use and is painless. While both Xyosted™ and Natesto® offer minimal chance for accidental transmission of testosterone, Natesto® provides additional benefit. The treatment is nasally administered, offers discreet dosing, and provides a measured delivery of testosterone.

Other benefits press the case for Natesto®. The product requires no special diet, no injection site pain, and perhaps most importantly from a safety perspective is that it is the ONLY currently marketed topical TRT without the severe FDA administered Black Box warning applied to its label. Safety is critical but efficacy is what men demand, and Natesto® checks that box as well.

Natesto® has provided an improvement in mood, increased erectile function, and has shown minimal impact on luteinizing and follicle stimulating hormones, and hematocrit levels, which cannot be claimed by the currently marketed alternatives, especially the injectable testosterone products. Compared to others outside of Xyosted™, like AndroGel® and Axiron®, Natesto® may be positioned to earn substantial share based on its safety, its proven efficacy value, and its ability to do its job without interfering with critical human hormone levels.

While eliminating much of the concern for the accidental transference of testosterone, Natesto®, in clinical studies, demonstrated meaningful improvement in all areas of erectile function, showed improvement in over 90% of patients that used the product and is showing superiority on many product levels. With these advantages proven, Aytu’s Natesto® is well positioned to benefit from a market in need of a safe product that limits unintended use and provides substantially better benefit to patients.

Now that AYTU has shown what Natesto® can do, the company has built a dedicated sales-force to drive prescription rates higher, and institutional investors demonstrated their support by participating in a recent $11.8 million private placement. The level of interest in that deal shows a belief that the company can emerge as a contender in the TRT space. But, while the potential is vast, assuming that AYTU grabbed only a 5% share of the existing $2 billion market, recognizing revenue over $100 million would indeed serve as a means to drive the company value sharply higher. And, if a 5% initial market penetration gets earned, then investors may expect the significantly undervalued market cap of roughly $15 million to likely get replaced with a value more representative of their peers, representing a significant opportunity for investors at these levels.

Wiser Choice

While both stocks are low priced, the unexplainable market-cap variance between ATRS and AYTU may present an enormous opportunity to those that favor Aytu BioScience. Many investors enjoy the fact that regulatory uncertainties are already behind Aytu. They are further impressed that Natesto® is earning sequential traction in prescription rates over the past three-quarters. In addition to Natesto® ‘s growing strength in the TRT market, as mentioned, Aytu recently completed an $11.8 million private placement and has enough cash on hand to lead the company to break-even or EPS territory, a milestone that may occur within the next twelve months. With just over 4 million shares outstanding and a float that is small, any hint of continued good news may serve as a spring board to the upside for investors that are looking for both near and long-term growth opportunity.

In the analysis of Antares and Aytu, the “Wiser Choice” is Aytu BioScience. While ATRS may work its way higher if Xyosted™ gets approved, at current levels investors appear not to have too much promise in its market potential. An argument may get shared that Aytu’s stock price is indicative of its opportunities with Natesto®. However, I find that argument to be moot, and most every metric for potential success for Natesto® is lining up as it should. Many insurers are covering the product, Natesto® has proven to be the safest treatment in its class, and has a price tag that may be considerably less than an approved Xyosted™.

With a significant market opportunity, veteran management, and a solid balance sheet in place, the value in Aytu’s Natesto® is beginning to deliver results and strengthen the revenue stream, which should provide the juice necessary to drive shareholder value higher.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 279
Nabriva Therapeutics PLC – ADR NBRV Stock News

Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) is off to an incredibly strong start in the early hours of today’s trading session and for good reason. The company released clinical data with regard to a key trial that proved to be overwhelmingly positive. Of course, this led to excitement among investors who are pushing the stock toward the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:06), NBRV is trading at $12.40 per share after a gain of $5.54 per share or 80.83% thus far today.





NBRV Gains On Strong Clinical Data

As mentioned above, NBRV is having an overwhelmingly strong start to the trading session this morning after the company announced positive top-line data from a key clinical trial. The trial, known as LEAP 1 was designed to evaluate the safety and efficacy of intravenous to oral lefamulin in patients with community acquired bacterial pneumonia. This is a key treatment as CABP is the leading cause of infectious death in the United States.




The data comes from the first of 2 pivotal Phase 3 clinical trials surrounding lefamulin. According to the press release offered by Nabriva Therapeutics, the trial met the United States Food and Drug Administration primary endpoint of non-inferiority when compared to moxifloxacin with or without adjunctive liezolid for early clinical response assesed 72 to 120 hours following initiation of therapy in the intent to treat population. The company announced that ECR rates were 87.3% for lefamulin and 90.2% for moxifloxacin with or without linezolid. In a statement, Dr. Colin Broom, CEO at NBRV, had the following to offer:

These Phase 3 data provide strong evidence of the potential of lefamulin to treat adults with CABP and provide an alternative to a current gold standard treatment regimen… Due to lefamulin’s flexible dose and targeted spectrum of activity against the pathogens most commonly associated with CABP, including multidrug-resistant strains, we believe that lefamulin is well suited to be a first-line empiric monotherapy. I am extremely proud and appreciative of the Nabriva Therapeutics team that has advanced lefamulin, which has the potential to be the first in a new class of antibiotics for CABP in more than 15 years, from initial discovery in our labs to this important milestone. We continue to execute on our second pivotal trial evaluating oral lefamulin for the treatment of CABP, with enrollment expected to complete in the fourth quarter of 2017 and topline results anticipated in the spring of 2018.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on NAVB. In particular, we’re interested in following the continued development of lefamulin as the treatment seems to be an overwhelmingly promising new option for treating CABP. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 768
Clovis Oncology CLVS Stock News

Clovis Oncology Inc (NASDAQ: CLVS) is having an interesting start to the trading session this morning. While we have seen quite a bit of up and down this morning, the stock is currently spiking as the result of a takeover rumor. Of course, if a takeover were to happen, it would lead to an incredible return of value for investors. As a result, the rumor is causing quite a bit of excitement. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:10), CLVS is trading at $71.03 per share after a gain of $1.57 per share (2.26%) thus far today.





CLVS Gains On Takeover Rumors

As mentioned above, Clovis Oncology is having an incredibly strong start to the trading session this morning as rumors surface surrounding the company. According to the rumors, a takeover offer has been made by Eli Lilly & Co. (NYSE: LLY). The rumors suggest that LLY has put an offer in to take CLVS over at a price of $110 per share, representing an overwhelmingly strong premium, given the current price on the stock.




While this rumor is indeed exciting, it’s important to remember that rumors, especially takeover rumors, are nothing new to the market. In fact, we see them just about every day. Nonetheless, market rumors are just like any other rumor. They are largely invalid. While this particular rumor has quite a bit more detail than most others in the market and the idea of a LLY takeover of CLVS is very practical, there has been no confirmation from either side of the fence. As a result, it’s important that if you do trade based on this rumor, you do so with caution.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will keep a close eye on CLVS and LLY. In particular, we’re interested in learning if the rumored takeover offer is valid. Of course, if the rumors are correct and CLVS does indeed take the offer, we’ll see a strong return of value to investors. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Himax Technologies HIMX Stock News

Himax Technologies, Inc. (ADR) (NASDAQ: HIMX) is having an overwhelmingly strong start to the trading session this morning. While the company hasn’t released any news this morning or over the weekend, there are rumors surfacing that we believe to be the cause for the gains. As is normally the case, our partners at Trade Ideas were the first to alert us to the movement. At the moment (9:48), HIMX is trading at $10.89 per share after a gain of $0.34 per share (3.18%) thus far today.





HIMX Gains On Rumors

As mentioned above, Himax Technologies is having an overwhelmingly strong start to the trading session today as rumors surface surrounding the company. The rumors suggest that the company has been awarded a new contract. However, they are also overwhelmingly vague. While there is an insinuation that a new contract has been awarded, there is no news with regard to who awarded the company the contract, what the contract is for, nor how much revenue the contract will drive.




Any time we see rumors in the market, as is the case with HIMX at the moment, we feel it’s important to remind investors that this is nothing new. The truth of the matter is that rumors are a daily occurrence in the stock market. Like most rumors, market rumors tend to lack validity. In this particular case, we urge those who plan on making moves based on this rumor to use caution. At the end of the day, it is overwhelmingly vague and seemingly impossible to track to the source. These tend to be the trademarks of false rumors designed to drive movement in the market.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on HIMX. In particular, we’re interested in following the company to see if the rumors of a new contract being awarded are true or not. While we don’t believe the rumor, anything can happen in the market. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 339
Pluristem Therapeutics Inc. PSTI Stock News

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is off to an incredibly strong start to the trading session this morning after the company announced that the FDA has granted Fast Track Designations to one of their pipeline drugs. As we have grown to expect, the news was overwhelmingly exciting to investors who are pushing the stock toward the top. Of course, our friends at Trade Ideas were the first to alert us to the gains. At the moment (9:30), PSTI is trading at $1.58 per share after a gain of $0.24 per share or 17.99% thus far today.





PSTI Gains On Fast Track Designation

As mentioned above, Pluristem Therapeutics is having an overwhelmingly strong start to the trading session today after the company announced some key FDA news. In a press release offered early this morning, the company announced that the United States Food and Drug Administration has granted Fast Track Designation surrounding PLX-PAD cells for the treatmnet of Critical Limb Ischema in patients that are ineligible for ravascularization.




As a result of the Fast Track Designation, PSTI will enjoy an expedited review process surrounding PLX-PAD. This will ultimately help the company bring the treatment to market at a faster rate should it qualify to be commercialized in the United States. In a statement, Zami Aberman, Chairman and Co-CEO at PSTI, had the following to offer:

We are extremely pleased with the FDA’s decision to grant Fast Track Designation to PLX-PAD in the treatment of CLI. Up to 40% of patients with CLI are ineligible for revascularization and are at high risk of amputation and death within the first year of diagnosis. This disease takes a heavy toll on patients and their families, while the cost of treating CLI in the U.S. alone is estimated at over $25 billion per year. We are working tirelessly to provide a cell therapy that will address this severe unmet medical need.”

The above statement was followed up by Yaky Yanay, President and Co-CEO at PSTI, with the following:

Regulators in some of the largest healthcare markets in the world are now in alignment regarding the need for accelerated approval pathways for our cell therapy product in the treatment of CLI. Programs like the Fast Track Designation offer real hope for patients battling this disease and we look forward to accelerating the path to market for PLX-PAD.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on PSTI. In particular, we’re interested in following the ongoing development surrounding PLX-PAD as well as other treatments in the company’s impressive pipeline. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 6538
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...